TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants with Clinically Significant changes in Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SCORing Atopic Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Long-term Stent Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tolerability (grade 3 or higher toxicities)
Endpoint domain: Adverse events/effects
Primary endpoint: Discharge time to PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutralizing antibodies to HPV serotypes 6, 11, 16 and 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abdominal comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Objective Response (Complete Response + Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ability to correctly assemble and use the X-PLO2R POC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondria related genes expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Plasma Concentration Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leakage in the CPAP system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb loss
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Inflammatory Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Onset of symptom improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effectiveness of Iberogast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Primary care physician satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HbA1C (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fasting glucose (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of MAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Real overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Mean Daily Diary Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Concentration-time Curve (AUC[0-t]) for Total-OCA at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) for Total-OCA at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Trough Concentration (Ctrough) for Total-OCA at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VS growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Oxygen Level dependent (BOLD) signal activity in Anterior Cingulate Cortex (ACC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disease-Free Survival (DFS) at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: HIV-1 RNA viral load suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in 6-minute walk test (6MWT) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fertility and pregnancy related issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: FNAC non diagnostic Bethesda 1 results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hair Density Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in dietary components from Baseline to 37 Weeks Gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enteral Nutrition Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance for ingested dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm concentration of 1 million/ml or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pathology (histological assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle oxigeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Lesions With a Clear or Almost Clear Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Antibody and T Cell-mediated Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with elevated markers (IL17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in thigh muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Standardized uptake value of 177Lu-EB-PSMA617
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrahepatic triglyceride (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical activity of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehensive clinical assessment of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Caregiver Burden From Baseline
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Frequency of Patient Problematic Behavioral Patterns From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Caregiver Depression From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Hand Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global incidence of grade II-IV acute graft versus host disease (GVHD) requiring rimiducid treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicity (DLT) of BPX-501
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in upper lid retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with circulating filarial antigenemia (CFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with IgG4 antifilarial antibodies in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with microfilaremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Response Rate for Achieving a 2 Grade Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients clinically and bacteriologically free of urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients clinically and symptomatologically free of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalisation severity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of Covid-19 symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inducible Myocardial Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial Dysfunction (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with CD9+ and CA9+ exosomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Suppression of nasal polyp-induced symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Potentially Eligible Participants Actually Enrolled Into the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Enrolled Who Remained in the Study and Completed the Post-Intervention Follow-Up Survey
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant Satisfaction Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assessment of olfactory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickening measured by optical coherence tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colony Forming Units (CFUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: prevalence of diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: associated cardiometabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: associated infectious risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Use of Emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Modification of the Sleeping Leeds Test
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Accuracy of Dexcom G6 Continuous Glucose Monitor (CGM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute change in eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incident cases of aggressive fibromatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Primary stability by ostell device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patency of AV fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of patients with low cardiac output syndrome after mitral valve surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to the Resumption of Bowel Functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of Grade 4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of CGM System (MARD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Responses (Complete and Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative urinary recovery of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative fecal recovery of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mass balance as a sum of the percent of total radioactivity recovered in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achieving the target systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in nutritionally related biochemical measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Requirement of invasive mechanical ventilation for more than 96 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of Hb Oxymeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of cortical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of CIPN associated symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of full completion of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tolerability in terms of acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDG-PET imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to task completion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 0 on Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Posterior Cingulate Cortex Perfusion at Hour 4 on Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients Reported to Have Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of vaso-occlusive (painful) crisis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary edema or congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants achieving live birth
Endpoint domain: Mortality/survival
Primary endpoint: audiometric test performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of urolithiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Virological Response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Six Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dopamine receptor availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of contraceptive methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Seizure reduction of 50% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Morbidity after colorectal surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality after colorectal surgery
Endpoint domain: Mortality/survival
Primary endpoint: Functional gain as measured by motor FIM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Psychiatric Rating Scale for Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perfusion of the skin microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation of the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic and asymptomatic catheter-related venous thrombosis (CVRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of catheter occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of catheter-related bloodstream infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC[0-tlast])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core Temperature at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to symptom relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functioning anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: No occurrence of adverse events related to device use
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of periodontal diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaerobic Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pupillary movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOL rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Volume change for the treated areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC50 of propofol for i-gel insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance on a questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Need for admissions to NICU secondary to TTN
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient Reported Outcome of Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Patient Reported General Health State
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Functional Health Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants With Maximum Heart Rate Increase During Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Maximum Heart Rate Increase During Salbutamol Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Heart Rate During Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Heart Rate (HR) During Salbutamol Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of clinical pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Atorvastatin AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total NNAL at Week 8 Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CPD based on 7 day IVR before week 8 visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects experiencing neurologic adverse event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Time of application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients need local anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Pain Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Variations of the Cardiac Index (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Walk Dynamic Motor Control Index 6-months After Orthopaedic Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Walk Dynamic Motor Control Index 1-year After Orthopaedic Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End stage renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Retention of bridges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Mindfulness skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in perceptions of infertility self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incident carotid artery plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 3 Month Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interproximal Bone Height Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression-free survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Composite Score of Abdominal Pain, Abdominal Bloating and Meteorism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Progression to Small Bowel Transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes